BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 2
• 3
• 4
• 5
• 6
• 7
• 10
• 11
• 12
• 13
• 14
• 17
• 18
• 19
• 20
• 21
• 24
• 25
• 26
• 27
• 28

• 

  Obesity

  Zealand Freezes Mid-Stage Obesity Asset To Focus on More Differentiated Drugs

  The decision to pause dapiglutide will help Zealand focus investment into assets that have “the greatest potential for clinical differentiation” in obesity.

  November 13, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Layoffs

  AbbVie Ends 11-Year Relationship With Calico, Lays Off 100+

  In January, AbbVie and Calico’s fosigotifator failed to show significant signs of efficacy in the HEALEY ALS platform trial for amyotrophic lateral sclerosis.

  November 13, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Job Trends

  21 Companies Miss Massachusetts Hiring Targets, Affecting Hundreds of Jobs

  Nearly two dozen life sciences companies that were awarded Massachusetts tax incentives to create and retain about 1,000 combined jobs hit just 13% of that target in 2024. Ten awardees had reported layoffs last year, including Charles River Laboratories and Moderna.

  November 13, 2025

   · 

  6 min read

   · 

  Angela Gabriel
• 

  Job Trends

  When, Not If: Job Market Should Start Turning Around in Next Year or So, Experts Say

  While most BioSpace LinkedIn poll respondents believe the job market won’t improve until at least 2027, two industry experts are optimistic a turnaround could start sooner. They discuss early signals of recovery and challenges that remain.

  November 13, 2025

   · 

  6 min read

   · 

  Angela Gabriel
• 

  FDA

  FDA Action Alert: BMS, Bayer, Arrowhead and More

  One of the FDA’s potential approvals this month could break an existing monopoly in the treatment space for a rare growth disorder.

  November 13, 2025

   · 

  5 min read

   · 

  Tristan Manalac
• 

  China

  Recently Launched Third Arc Turns to China for Cancer T Cell Engagers

  The back-heavy deal includes a $5 million upfront payment for two novel T cell engagers, though the companies have yet to disclose priority indications.

  November 13, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Rare diseases

  FDA Unwraps ‘Plausible Mechanism Pathway’ for Personalized Therapies

  The plausible mechanism pathway “could accelerate gene therapy/editing development,” analysts at William Blair said Thursday, while adding that additional clarity is needed.

  November 13, 2025

   · 

  3 min read

   · 

  Tristan Manalac
• 

  Neuroscience

  Alkermes Pushes Narcolepsy Program to Phase III With ‘Highly Competitive’ Mid-Stage Data

  Alixorexton’s Phase II performance sets it up for late-stage success, according to analysts at Truist Securities. Alkermes expects to launch a global late-stage program early next year for narcolepsy type 2.

  November 13, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  IN PARTNERSHIP WITH SLONE PARTNERS

  How Biotech Funding is Changing Executive Search and Hiring Processes

  In this episode presented by Slone Partners, Leslie Loveless, Co-CEO and Managing Partner discusses how hiring and the building of executive teams has responded to the current biotech environment.

  November 13, 2025

   · 

  1 min read

   · 

  BioSpace Insights
• 

  RNA editing

  Korro Suffers Cacophony of Bad News as Lead Candidate Fails, Novo Pauses RNA Deal

  Korro Bio is moving back to square one as a preclinical biotech after the failure of KRRO-110 in alpha-1 antitrypsin deficiency. The company’s stock is down 80% on all the news.

  November 13, 2025

   · 

  3 min read

   · 

  Annalee Armstrong